CUB domain-containing protein-1 (CDCP1) is a transmembrane glycoprotein that is phos-phorylated by SRC family kinases (SFK) before recruiting and activating PKCδ. CDCP1 is overproduced in many cancers. It promotes metastasis and resistance to anoïkis. The ro-bust production of CDCP1 would be associated with stemness and has been proposed as a novel prognosis marker. The natural transmembrane location of CDCP1 makes it an ideal therapeutic target and treatments based on the use of appropriate antibodies are currently being evaluated. However, we still know very little about the molecular fate of CDCP1 and its downstream signaling events. Improvements in our understanding of the molecular events occurring downstream of CDCP1 are required to m...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
CUB domain-containing protein-1 (CDCP1) is a transmembrane glycoprotein that is phosphorylated by SR...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
PURPOSE: Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting N...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CD...
The function of CUB domain-containing protein 1 (CDCP1), a recently described transmembrane protein ...
CUB-domain-containing protein 1 (CDCP1) is an integral membrane glycoprotein with potential as a mar...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
THEMIS is critical for conventional T-cell development, but its precise molecular function remains e...
Tissue inhibitors of metalloproteinases (TIMPs) are the endogenous inhibitors of the matrix metallop...
protein, whose phosphorylation is under the control ofactivated receptor tyrosine kinases (RTKs) suc...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
CUB domain-containing protein-1 (CDCP1) is a transmembrane glycoprotein that is phosphorylated by SR...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
PURPOSE: Despite recent approvals for checkpoint inhibitors and antibody-drug conjugates targeting N...
CUB Domain Containing Protein 1 (CDCP1) is a transmembrane glycoprotein that has mainly been implica...
The transmembrane glycoprotein, CUB (complement C1r/C1s, Uegf, Bmp1) domain-containing protein 1 (CD...
The function of CUB domain-containing protein 1 (CDCP1), a recently described transmembrane protein ...
CUB-domain-containing protein 1 (CDCP1) is an integral membrane glycoprotein with potential as a mar...
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the ...
THEMIS is critical for conventional T-cell development, but its precise molecular function remains e...
Tissue inhibitors of metalloproteinases (TIMPs) are the endogenous inhibitors of the matrix metallop...
protein, whose phosphorylation is under the control ofactivated receptor tyrosine kinases (RTKs) suc...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
CUB domain containing protein 1 (CDCPl) is an integral membrane glycoprotein that has been implicate...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...
Background: Development of targeted therapies for high-grade serous ovarian cancer (HGSC) remains ch...